Jianjun Luo

Prof. Jianjun Luo

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
JMJingqin Ma
Jingqin Ma
XGXiming Gong
Ximing Gong
JLJianjun Luo
Jianjun Luo
JGJunying Gu
Junying Gu
ZYZhiping Yan
Zhiping Yan
MYMinjie Yang
Minjie Yang

1 January 2011 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
JLJianjun Luo
Jianjun Luo
ZYZhiping Yan
Zhiping Yan
JWJian-Hua Wang
Jian-Hua Wang
QLQingxin Liu
Qingxin Liu
XQXuDong Qu
XuDong Qu

5 January 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
TYTian-Zhu Yu
Tian-Zhu Yu
WZWen Zhang
Wen Zhang
QLQing-Xin Liu
Qing-Xin Liu
WLWen-Hui Li
Wen-Hui Li
JMJing-Qin Ma
Jing-Qin Ma
ZYZhiping Yan
Zhiping Yan
Endovascular brachytherapy combined with portal vein stenting and transarterial chemoembolization improves overall survival of hepatocellular carcinoma patients with main portal vein tumor thrombus Endovascular brachytherapy combined with portal vein stenting and transarterial chemoembolization improves overall survival of hepatocellular carcinoma patients with main portal vein tumor thrombus

1 July 2018 in Brachytherapy
Verified
Journal Article
Closed access
JMJingqin Ma
Jingqin Ma
JLJianjun Luo
Jianjun Luo
JGJunying Gu
Junying Gu
QLQingxin Liu
Qingxin Liu
LLLingxiao Liu
Lingxiao Liu
ZYZhiping Yan
Zhiping Yan

2 May 2013 in CardioVascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
WZWen Zhang
Wen Zhang
ZYZhiping Yan
Zhiping Yan
JLJianjun Luo
Jianjun Luo
ZFZhu-ting Fang
Zhu-ting Fang
LWLinlin Wu
Linlin Wu
JWJianhua Wang
Jianhua Wang

1 March 2021 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
YZYongjie Zhou
Yongjie Zhou
XZXin Zhou
Xin Zhou
JMJingqin Ma
Jingqin Ma
WZWen Zhang
Wen Zhang
ZYZhiping Yan
Zhiping Yan
JLJianjun Luo
Jianjun Luo
Background: Only a few studies have investigated the clinical features and outcomes of patients with pulmonary metastasis from hepatocellular carcinoma (HCC) at the initial diagnosis. This study aimed to evaluate the prevalence, risk factors and prognostic factors related to pulmonary metastasis and then construct a nomogram to predict the outcomes of patients with HCC presenting with pulmonary metastasis. Methods: The Surveillance, Epidemiology, and End Results (SEER) database was used to select patients. A total of 25,236 eligible patients diagnosed with HCC from 2010 to 2015 were selected. Then, 897 patients with HCC presenting with pulmonary metastasis at the initial diagnosis were included in the primary set (n=598) and validation set (n=299). Logistic and Cox regression analyses were used to determine the risk factors and prognostic factors for pulmonary metastasis. A nomogram predicting the prognosis of patients with HCC presenting with pulmonary metastasis was constructed based on independent prognostic factors identified in Cox regression analyses. Both internal and external validations of the nomogram were performed using discrimination and calibration plots. Results: The prevalence of pulmonary metastasis was 3.6% (897/25,236) in the entire cohort diagnosed with HCC as the initial diagnosis. Age, race, Edmonson-Steiner classification grade I/III, higher T stage, N stage, alpha fetoprotein(AFP) levels, brain metastasis, bone metastasis and intrahepatic metastasis were positively correlated with the development of HCC with pulmonary metastasis at the initial diagnosis. Prognostic factors incorporated in the nomogram were sex, T stage, bone metastasis, AFP levels, treatment, radiation and chemotherapy. The concordance index (C-index) of the nomogram in the primary set was 0.661 (95% CI: 0.633– 0.688), indicating considerable predictive accuracy. The calibration curves showed consistency between the nomogram and the actual observations. When the nomogram was applied to the validation set, the results also remained reconcilable, and the C-index of the nomogram was 0.657 (95% CI: 0.626– 0.698). Conclusion: A list of risk factors associated with pulmonary metastasis occurrence in patients with HCC was selected, and the nomogram accurately predicted the prognosis of patients with HCC presenting with pulmonary metastasis at the initial diagnosis.